HUJI MGC Pharma DC2: Liver, Gut and Kidney disorders

Project 1: Nanodelivery of cannabinoids for treating NAFLD (nonalcoholic fatty liver disease)

Obesity is a chronic disease that has been described as a catalyst for a number of conditions, most notably is nonalcoholic fatty liver disease (NAFLD). The endocannabinoid (eCB) system, involved in the development NAFLD, has been shown to regulate hepatic glucose production, insulin resistance and de novo lipogenesis. Accordingly, targeting the diseased liver by using cannabinoids encapsulated in nano delivery system can be a therapeutic approach to ameliorate NAFLD.

Supervisors: A/Prof. Yossi (Joseph) Tam (HUJI) and A/Prof. Nitin Manti (RMIT) and A/Prof Charlotte Conn (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma) 

Project 2: Nanodelivery of cannabinoids for kidney disorders

Kidney diseases represent a global concern due to their elevated and rapidly growing incidence. Over the past two decades, the incidence of chronic kidney disease (CKD) and acute kidney injury (AKI) has dramatically increased, with limited available therapy. Targeting the diseased kidney with nano encapsulated cannabinoids could be therapeutically relevant as the endocannabinoid system is known to modulate kidney function in health and disease. 

Supervisors: A/Prof. Yossi (Joseph) Tam (HUJI) and A/Prof. Nitin Manti (RMIT), A/Prof Charlotte Conn (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma) 

Project 3: Nanodelivery of cannabinoids for gut disorders

We will develop nanoparticulate systems for oral delivery of cannabinoids and study their impact on gut microbiome metabolism. The gut microbiota synthesizes a variety of chemical compounds, acting as a functional complement to host metabolism. Changes in gut microbiota metabolism can cause or cure various inflammatory disorders of the gut. We will map the distribution of cannabinoids along the GI tract and evaluate their impact on spatial microbiome metabolism using mass spectrometry imaging.

Supervisors: Dr Katy Margulis (HUJI) and A/Prof. Nitin Manti (RMIT) and A/Prof Charlotte Conn (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma)

Share on facebook
Share on twitter
Share on linkedin
Share on email

Reference

HUJI MGC Pharma DC2

Research Areas

Biomedical Sciences, Nanotechnology, Applied science, Chemistry and Pharmacy 

Research Host

Hebrew University of Jerusalem (HUJI)

PhD awarding institution/s

Hebrew University of Jerusalem (HUJI) - RMIT University

Location

Israel

Status

Closed Position

RMIT University

Other Positions

Supervisors

Associate Prof. Andrey Molotnikov (RMIT), Professor Dr.-Ing. Thomas Niendorf (UoK), Philipp Krooss (UoK) and Dr. Markus Weinmann (UoK)

PhD awarding institution/s

University of Kassel (UoK) and RMIT University

Location

Germany

Status

Open Position

Supervisors

Prof. Jenny Zhang (RMIT) and Prof. Jose Antonio Vilar-Fernandez (UDC) and José Luis González Leal (Navantia) and Prof. Amparo Alonso-Betanzos (UDC) and Prof. Vicente Díaz-Casas (UDC) and Prof. Marcos Miguez González (UDC)

PhD awarding institution/s

University of A Coruña (UDC) and RMIT University

Location

Spain

Status

Open Position

Supervisors

Prof. Anne-Laure Mention (RMIT) and Associate Prof. Carsten Nico Hjortso (UPCH) and Dr. Marie Smed (UPCH)

PhD awarding institution/s

University of Copenhagen (UCPH) and RMIT University

Location

Denmark

Status

Open Position

RMIT and many of the REDI partners are HSR4R certified
europe-1-1.svg

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101034328.

Results reflect the author’s view only. The European Commission is not responsible for any use that may be made of the information it contains